Journal of Oncology

Glycoconjugates in Cancer


Publishing date
01 Jan 2020
Status
Closed
Submission deadline
13 Sep 2019

Lead Editor

1Northwest University, Xi’an, China

2National Center for Nanoscience and Technology, Beijing, China

3Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil

This issue is now closed for submissions.
More articles will be published in the near future.

Glycoconjugates in Cancer

This issue is now closed for submissions.
More articles will be published in the near future.

Description

Cancer cells, in contrast to normal cells, display uncontrolled cell growth and high motility or invasiveness, which are closely related to the process of metastasis. Glycoconjugates, including glycoproteins, proteoglycans, and glycolipids, are abundant in mammalian cells. Glycans (sugar residues in glycoconjugates) often function as signaling effectors and cell recognition markers. Aberrant glycosylation and dysregulated responding glycosyltransferases or glycosidases occur essentially in the development and progression of human cancers, and many glycosyl epitopes constitute tumor-associated antigens.

Glycosylation is generated by complex biosynthetic pathways comprising hundreds of glycosyltransferases, glycosidases, transcriptional factors, ion channels, and other proteins. In addition, absence of direct genetic templates and glycospecific antibodies, as was commonly used in DNA amplification and protein capture, makes research on glycans and glycoproteins even more difficult. The discovery of aberrant glycans and exploring their underling mechanisms would expand their applications as diagnostic markers or therapeutic targets for cancers.

Increasing research effort has been paid toward development of novel methods of glycan analysis, including glycogen-based DNA microarrays, lectin microarrays, and mass spectrometry (MS). Application of these approaches in glycan analysis have allowed new opportunities and approaches for investigating cancer-related proteomics and glycomics. This special issue welcomes review papers and original research articles focusing on the pathogenesis and biomarker identification of glycoconjugates in the cancer field.

Potential topics include but are not limited to the following:

  • Functional implications of altered glycosylation in cancer
  • O-GlcNAcylation and its mechanisms in cancer development
  • Intracellular mechanisms of specific glycosyltransferases with respect to their targets in cancer
  • Glycosylation of specific proteins in serum or tumor tissues as a diagnostic biomarker or in patient prognosis and treatment responses
  • Advanced techniques of glycoproteomics in dissecting cancer pathogenesis
Journal of Oncology
 Journal metrics
Acceptance rate33%
Submission to final decision93 days
Acceptance to publication48 days
CiteScore3.220
Impact Factor2.600
 Submit